We have investigated the therapeutic potential of a prototypic melanoma vaccine based on recombinant adenovirus expressing human dopachrome tautomerase in the B16F10 murine melanoma model. We found that in the presence of a tumor, the magnitude of T-cell immunity evoked by the vaccine was significantly reduced. This impairment was compounded by defects in cytokine production and degranulation within the tumor-infiltrating lymphocytes (TILs). We showed that the combination of vaccination with high-dose cyclophosphamide was able to skew the response toward the target antigen and enhanced both the quantity and quality of antigen-specific CD8 þ and CD4 þ T-cell responses in tumor-bearing mice, which resulted in the inhibition of tumor growth. Furthermore, when tumor-specific antigens were targeted by the vaccine, the combination therapy could actually produce tumor regression, which appeared to result from the high frequency of antigen-specific T cells. These data show that recombinant adenovirus vaccines are compatible with conventional high-dose chemotherapy and that the combined treatment results in improved therapeutic outcomes relative to either agent individually.
Introduction
The identification of tumor-associated antigens (TAAs) has provided a platform for the development of cancer vaccines with the promise of eradicating antigen-positive tumor cells. Although tumor vaccines can routinely provide complete protection from tumor challenge when used in a prophylactic setting, they exhibit reduced efficacy when applied in a therapeutic setting. [1] [2] [3] To make the best use of tumor vaccines, one strategy would be to use them under conditions of reduced tumor burden. Indeed, certain combinations of conventional cytotoxic therapies with cancer vaccines have been associated with improved therapeutic outcomes in murine models. [4] [5] [6] [7] Although this approach may seem counterintuitive as cytotoxic therapies often result in lymphopenia, which could limit the availability of T and B lymphocytes, several recent studies have shown that lymphopenia conditions may actually increase T-cell responsiveness to cancer vaccines. [8] [9] [10] [11] The lymphopenic environment provides more physical space as well as abundance of cytokines and growth factors to promote expansion and differentiation of lymphocytes. In fact, it has been shown that the requirements for T-cell activation under lymphopenic conditions are less stringent and naive T cells can acquire effector-like phenotype and function despite not having been primed through the conventional T-cellantigen-presenting cell interactions. 12, 13 Therefore, immunization in a lymphopenic host may provide an opportunity to skew the T-cell response toward the vaccine antigen and augment the antitumor effect.
We have been investigating the therapeutic utility of replication-defective adenovirus (rAd)-based cancer vaccines. Comparison of rAd vaccines expressing a number of melanoma-associated antigens, including gp100, tyrosinase, tyrosinase-related protein 1 (TRP-1) and TRP-2/ dopachrome tautomerase (DCT), revealed that a rAd vector expressing human TRP-2/DCT (rAdhDCT) provided the greatest protection against the B16F10 murine melanoma [14] [15] [16] [17] (unpublished data). TRP-2/DCT is a nonmutated TAA that is widely expressed in melanoma and a promising candidate for the development of melanoma vaccines as it is naturally recognized by cytotoxic T lymphocytes (CTLs) specific for human and murine melanomas. [18] [19] [20] In our earlier study, we showed that it is feasible to vaccinate mice with rAd expressing a foreign antigen under conditions of extreme leukopenia induced by lethal irradiation. 21 Importantly, we showed that vaccination of myeloablatively treated animals reconstituted with autologous bone marrow generates antigenspecific T cells, which are functionally indistinguishable from those generated in wild-type (WT) mice. Thus, we reasoned that conventional cytotoxic treatments that induce partial lymphopenia should be compatible with rAd vaccination. In our current study, we investigated whether therapeutic vaccination with AdhDCT under conditions of partial leukopenia induced by high-dose treatment with non-myeloablative cytotoxic agents would benefit from homeostatic expansion and result in an improved therapeutic outcome.
Results

Prophylactic and therapeutic vaccination against B16F10 using AdhDCT in WT mice
We, and others, have shown that immunization with AdhDCT can produce robust protective immunity against challenge with B16F10. 1, 3, 14, 15, 22, 23 To assess the efficacy of this vaccine in a therapeutic setting, mice bearing 5-day-old tumors (average tumor size 3 Â 3 Â 1 mm) were either left untreated or vaccinated with AdhDCT or AdLCMV GP as a negative control. In this setting, vaccination with AdhDCT resulted in a greater suppression of tumor growth as compared with the controls, yet all the mice reached end point within 20 days after tumor injection ( Figure 1a) . Thus, despite the robust protection achieved in a prophylactic setting, immunization with AdhDCT provides only limited activity against 5-day-old established tumors.
To gain further insight into the limitations of AdhDCT as a treatment for growing tumors, mice were immunized at different times before or after challenge with B16F10 cells. Vaccination with AdhDCT 7 days prior to tumor challenge provided 100% protection (Figure 1b) , similar to our earlier results. 15 We could also achieve 70% protection when mice were immunized with AdhDCT 1 day prior to tumor challenge. However, when mice were vaccinated as early as 1 day after tumor inoculation, protection was fully abrogated, even though the tumor was not palpable at the time of vaccination (Figure 1b) . Increasing the vaccine dose to 10 9 pfu (plaque-forming units) resulted in a greater suppression of tumor growth in mice bearing 1-or 3-day-old tumors; however, tumors still grew in all mice (data not shown). Therefore, despite the fact that AdhDCT was able to provide complete protection in a prophylactic setting, this vaccine was much less effective when delivered as early as 1 day after tumor inoculation.
Characterization of vaccine-induced T-cell responses in tumor-bearing and tumor-free WT mice To determine whether the presence of tumor interferes with the immune response produced by AdhDCT immunization, tumor-free mice and mice bearing 5-day tumors were immunized with AdhDCT and the frequency of antigen-specific T cells was examined 7 days later. Strikingly, we found that the frequencies of both DCT 180À188 -specific CD8 þ T cells and DCT 88À102 -specific CD4 þ T cells were significantly reduced (approximately three-fold) in tumor-bearing mice as compared with tumor-free animals ( Figure 2a ). Interestingly, immunization of tumor-bearing animals with AdLCMV GP, which expresses a nontumor-associated antigen, yielded comparable numbers of LCMV GP 33À41 -specific CD8 þ cells and LCMV GP 61À80 -specific CD4 þ T cells as compared with those in tumor-free, AdLCMV GP-immunized mice (Figure 2b) . Therefore, it appears that tumor presence hampers systemic immunity against TAA.
We also examined the frequency of antigen-specific CD8 þ T cells within the tumor-infiltrating lymphocytes (TILs). Interestingly, vaccination with either AdhDCT or AdLCMV GP resulted in increased numbers of CD8 þ T cells within the TIL population (data not shown). Furthermore, despite the overall decrease in total numbers of DCT-specific T cells in tumor-bearing mice, the frequency of DCT-specific T cells as a function of the total T-cell population was higher in the tumor than in other tissues (data not shown) showing that DCT-specific T cells can accumulate within the tumor.
The functionality of DCT 180À188 -specific CD8 þ T cells was evaluated based on cytokine production and ability to degranulate. Despite differences in the magnitude of the T-cell responses, the fraction of interferon-g (IFN-g)-secreting CD8 þ T cells that can also produce tumor necrosis factor-a (TNF-a) and interleukin-2 (IL-2) was comparable in the spleens of both tumor-bearing and tumor-free mice (Figures 3a and b) . By contrast, TILs exhibited significantly diminished secretion of both TNFa and IL-2 as compared with CD8 þ T cells isolated from the spleen (Figures 3a and b) , suggesting that TILs are more limited functionally than circulating tumor-specific T cells. The defect in cytokine production was not a general phenomenon because LCMV GP 33À41 -specific CD8 þ T cells within the B16F10 tumors produced cytokines similar to the peripheral T cells (Figures 3c and  d) . Thus, it appears that the defect in cytokine production is specific for TAA. Indeed, LCMV GP 33À41 -specific CD8 þ T cells exhibited defects in TNF-a and IL-2 production when retrieved from B16GP33 tumors that express the LCMV GP 33À41 epitope (data not shown). We have observed that DCT-specific TILs express granzyme B (GrB) showing that these cells are capable of cytolytic activity (data not shown). However, DCT-specific TILs displayed clear defects in degranulation as determined by the percentage of CD8 þ IFN-g þ T cells that express CD107a on the cell surface after stimulation with cognate peptide (Figure 3e ). Although CD8 þ T cells obtained from peripheral tissues exhibited high capacity for degranulation regardless of the presence of tumor, CD8 þ T cells within the TILs uniformly exhibited a defect in degranulation irrespective of whether their cognate antigen was expressed by the tumor (Figure 3e and data not shown). Moreover, there was an inverse relationship between tumor size and capacity for degranulation (Figure 3f ). Therefore, it appears that two High-dose chemotherapy enhances tumor vaccination N Grinshtein et al distinct mechanisms are at play within the tumor that result in T-cell dysfunction. The first pathway is antigenspecific and is manifested as a defect in cytokine production and the second one is nonspecific and results in a generalized defect in degranulation.
Combining AdhDCT immunization with nonmyeloablative cytotoxic treatment improves survival of tumor-bearing WT mice We have shown earlier that rAd vaccines are active under conditions of extreme leukopenia and can skew the T-cell response toward the vaccine antigen. 21 Therefore, we reasoned that combining the AdhDCT vaccine with a cytotoxic agent may enhance the frequency of DCTspecific T cells in tumor-bearing mice. We also hypothesized that suppression of tumor growth may provide additional time for the T-cell response to develop and attack the tumor. Two cytotoxic treatments were investigated, sub-lethal irradiation and treatment with highdose cyclophosphamide (CTX). Both of these cytotoxic treatments augmented the frequencies of DCT-specific T cells when combined with AdhDCT in the tumor-free mice (data not shown).
Mice bearing 5-day-old B16F10 tumors were irradiated with 250 rads and immunized the day after irradiation with either AdhDCT or AdLCMV GP. However, the combination of irradiation and vaccination had no impact on tumor growth (Figure 4a ). Increasing the dose of irradiation to 550 rads did not change the outcome (data not shown).
Combining AdhDCT with high-dose chemotherapy was more successful. Mice received 150 mg kg À1 every other day for a total of three doses (the maximal-tolerated dose 24 ). This treatment resulted in a five-fold reduction in total cellularity in the spleen, reaching the nadir 1 day after the last CTX dose and recovering back to normal numbers within a week after treatment cessation (data not shown). Mice bearing 5-day-old B16F10 tumors were treated with CTX and immunized the day after the final dose. Tumor growth was significantly delayed by CTX treatment (Figure 4b) , and the combination of CTX and AdhDCT further inhibited tumor growth resulting in improved survival (Figure 4c ) as compared with the combined treatment with CTX and AdLCMV GP. Thus, the combination of a cytotoxic agent with AdhDCT can have a beneficial therapeutic effect when the tumor is sensitive to the cytotoxic agent. We attempted to enhance the therapeutic efficacy of AdhDCT by vaccinating the mice twice (1 week apart) after the CTX treatment and increasing the vaccine dose to 10 9 pfu; however, those Examining the effect of CTX on the immune response to AdhDCT in tumor-bearing hosts To further characterize the impact of CTX on AdhDCT immunization, DCT-specific immunity was monitored and compared with tumor-bearing mice that were immunized in the absence of CTX treatment. The kinetics of both the CD8 þ and the CD4 þ immune responses differed dramatically as a consequence of CTX treatment. Consistent with the earlier reported immune-enhancing properties of CTX, we observed that the frequencies of DCT-specific CD8 þ T cells were markedly increased in mice receiving CTX þ AdhDCT relative to AdhDCT alone (3.72±0.36% vs 1.75±0.18% at day 10 postimmunization (Po0.01); 6.36 ± 1.54% vs 0.68 ± 0.10% at day 15 (Po0.01)). Thus, our approach succeeded in skewing the immune response toward DCT. Furthermore, these increased frequencies translated into increased total numbers of DCT-specifc CD8 þ T cells at later times post-infection ( Figure 5a , day 15). Similar results were observed with DCT-specific CD4 þ T cells, although there was a delay in CD4 þ T cell expansion in the CTXtreated animals ( Figure 5a , right panel). Therefore, not only does the CTX treatment increase the overall magnitude of the DCT-specific immune response but also extends the duration of the response. We were not able to measure DCT-specific immunity in mice treated with CTX and immunized with AdLCMV GP (data not shown).
Earlier studies have shown that CTX may be more toxic to regulatory T cells than to conventional T cells, and, indeed, we observed that the frequency of CD4 þ FoxP3 þ T cells in the CTX-treated animals was significantly reduced a week after CTX treatment, but returned back to normal 2 weeks thereafter. However, total numbers of CD4 þ FoxP3 cells remained constant throughout the experiment (data not shown). Thus, we cannot conclude whether the increased magnitude of the DCT-specific T cell response after CTX treatment was because of the lymphopenic state within the immunized mice or depletion of regulatory T cells.
Functional assessment revealed that the frequency of DCT-specific cells capable of secreting IFN-g and TNF-a was significantly increased in the CTX-treated mice, in both the periphery and the tumor (Figure 5b , left panel). There was no difference in the ability of the DCT-specific CD8 þ T cell to produce IL-2 or undergo degranulation, regardless of CTX administration (Figure 5b, middle and right panels, respectively). Thus, in addition to augmenting T-cell response after vaccination, CTX also improved some aspects of T-cell functionality both systemically and locally.
Combining CTX treatment with vaccine expressing a foreign antigen can induce tumor regression In addition to non-mutated antigens, such as DCT, tumors express many tumor-specific antigens that arise from spontaneous mutations. 25 We reasoned that as DCT is a non-mutated antigen that is expressed in multiple tissues, tolerance mechanisms might interfere with an effective tumor rejection. Therefore, we opted to evaluate the combined CTX þ rAd vaccine strategy in a similar model where we targeted a tumor-specific antigen. For this experiment, we used a subline of B16F10, which stably expresses the LCMV GP 33À41 epitope, termed B16GP33. 26 WT mice were inoculated with B16GP33, treated with CTX 5 days later and immunized with either AdLCMV GP or AdLacZ as a control vector. Tumors grew progressively in all the mice treated with CTX þ AdLacZ (Figure 6a ). In contrast, tumor regression occurred in all the animals treated with CTX þ AdLCMV GP, resulting in a significant benefit to the overall survival (Figures 6a and b) . However, we also observed that tumors relapsed after initial regression in this model. 
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Further examination of the relapsed tumors revealed that they were no longer susceptible to LCMV GP 33À41 -specific immunity ( Table 1 ), suggesting that the development of tumor escape variants (TEVs) underlies the lack of long-term tumor regression in this model.
As the LCMVGP 33À41 epitope was introduced into the B16F10 cell line through genetic manipulation, it is possible that the development of TEVs is facilitated by instability of the exogenous sequences. Therefore, we opted to further investigate this question in the context of High-dose chemotherapy enhances tumor vaccination N Grinshtein et al an unmodified tumor cell population, where the foreign antigen is naturally expressed by the tumor. For this model, we used DCT-deficient mice, where DCT, which is naturally expressed in the B16F10 cells, will behave as a tumor-specific antigen as it is not expressed in the host. DCT-deficient mice bearing 5-day-old B16F10 tumors were treated with CTX and immunized with either AdhDCT or AdLCMV GP. Similar to the B16GP33 model, tumors grew progressively in mice treated with CTX and the control vaccine, whereas tumor regression was observed in all the animals treated with CTX þ AdhDCT (Figure 6c ), resulting in a significant benefit to the overall survival (Figure 6d) . Together, these data show that antigen selection plays a central role in the outcome of this treatment strategy. Nevertheless, despite initial regression, most of the tumors ultimately relapsed similar to our observations in the B16GP33 model. However, unlike the B16GP33 model, the tumors that grew back in DCT-deficient mice treated with CTX þ AdhDCT retained the expression of DCT and were sensitive to the DCT-specific immunity (Table 2) . Therefore, although TEVs can be limiting to this treatment regimen, this does not explain the regrowth of unmodified B16F10 tumors in DCT-deficient hosts.
Comparison of the T-cell response produced in tumor-bearing WT and DCT-deficient mice after CTX þ AdhDCT treatment To gain further insight into factors that influence the regression of B16F10 tumors after CTX þ AdhDCT treatment, we examined the magnitude of the DCTspecific T-cell response in tumor-bearing WT and DCTdeficient mice treated with CTX þ AdhDCT. We found that the frequencies of both CD8 þ and CD4 þ antigenspecific T cells were significantly higher in the DCTdeficient mice as compared with the WT animals (CD8 þ : 10.96 ± 1.56% vs 3.19 ± 0.38%, Po0.01; CD4 þ : 1.10 ± 0.27% vs 0.41 ± 0.15%, Po0.05), which translated to an approximate four-fold increase in the number of antigen-specific T cells (Figures 7a and b) . Consistent with the elevated frequencies of DCT-specific CD8 þ T cells, we observed markedly higher levels of CTL activity in vivo in DCT-deficient mice as compared with the WT mice (Figure 7c ). The DCT-specific CD8 þ T-cell population from both WT and DCT-deficient mice exhibited similar sensitivity to DCT 188À188 peptide as determined by comparing IFN-g production over a range of doses from 1ÀpM to 1 mM (data not shown), and thus the increased killing in vivo is likely because of the elevated number of CD8 þ T-cell effectors rather than differential avidity. Cytokine production and degranulation by DCT-specific CD8 þ T cells were comparable in DCT-deficient and WT mice in both the spleen and the tumor (Figure 7d ), although the frequencies of CD8 þ T cells producing both IFN-g and TNF-a were slightly reduced in DCT-deficient mice (Figure 7d, left panel) . Overall, our data suggest that there is little functional difference between the DCTspecific CD8 þ T cells elicited by the CTX þ AdhDCT regimen in WT and DCT-deficient mice, and that the difference in therapeutic outcome is a result of the elevated frequencies of DCT-specific T cells.
Discussion
In the current study, we show that rAd vaccines can be combined with conventional cytotoxic agents to achieve an improved therapeutic outcome consistent with our earlier report that rAd vaccines are not inhibited by extreme leucopenia. 21 Although the prototypic serotype 5 rAd vectors used in this report may be limited by preexisting immunity in humans, many novel rAd vectors have been developed based on rare human serotypes and adenoviruses from other species. Therefore, preexisting immunity to common human adenoviruses viruses is not likely to present a problem for the clinical translation of our results.
Several recent studies have also shown beneficial effects of combining vaccination with antineoplastic therapies. [8] [9] [10] 27, 28 In particular, a number of studies have investigated the combination of CTX with various vaccines. [4] [5] [6] [7] 29, 30 However, in most of those studies a low dose of CTX was used (single injection of 100 mg kg À1 or less) as a strategy to selectively deplete regulatory T cells. Rather than using a low dose of CTX, we used the maximaltolerated dose for two reasons: (1) to directly inhibit tumor growth and provide more time for the vaccine to function; and (2) to induce partial leucopenia and benefit from the High-dose chemotherapy enhances tumor vaccination N Grinshtein et al increased sensitivity of leucopenic hosts to the development of autoimmunity. Although the precise mechanisms by which CTX improves immunization are not known, various theories have been proposed including selective elimination of regulatory T cells, 7, [28] [29] [30] disturbing tumor stroma cell interactions, 31 induction of bystander effects on T cells 32 and stimulation of type I IFN. 33 Based on the results described herein, we believe that the beneficial effects of CTX can also be attributed to increased numbers of antigen-specific T cell and partial improvement of both systemic and local CD8 þ T-cell function.
The concept that successful T-cell-mediated tumor rejection is dependent on the available number of tumor-specific T cells is supported by recent data arising from adoptive T-cell transfer. In both murine models and human clinical trials, T-cell transfer provided remarkably high frequencies of tumor-specific T cells and produced durable tumor regression. 27, 34 These data argue that in spite of the numerous immune evasion strategies adopted by tumors, 35, 36 these mechanisms can be overcome by sufficiently high numbers of T cells. It is important to note that murine T-cell transfer models have revealed that central memory T cells are considerably more effective than effector memory T cells in their ability to evoke tumor regression. 37, 38 Therefore, not only is the quantity of the available T cells important but also is the quality. This observation presents a significant challenge for therapeutic vaccination. Although it may be possible to achieve sufficiently high numbers of T cells after vaccination using boosting strategies, the T cells will likely possess an effector phenotype. The development of vaccination strategies that selectively amplify central memory cells should prove useful. Indeed, it has been recently reported that peptide-pulsed dentritic cells (DCs) can lead to enhanced central memory formation after immunization. 39 We have examined DC vaccines in our therapeutic model but failed to obtain any benefit over AdhDCT (N Grinshtein, unpublished data).
The results from the current study offer new information regarding the possible limitations of effector cells in the context of the tumor microenvironment. It can be noted that DCT-specific CD8 þ T cells isolated from the tumor displayed impairments in both cytokine production and degranulation. It is interesting to point out that CD8 þ T cells circulating in the periphery did not exhibit similar defects. Our results are in agreement with a recent report of immunization with a peptide vaccine in two melanoma patients, where TILs revealed clear evidence of dysfunction that was not measured in the peripheral blood. 40 These data strongly suggest that strategies for immune monitoring should make greater effort to examine the functionality of the TILs. The impairment in cytokine production that we observed was not a general defect attributed to all tumor-infiltrating CD8 þ cells and it may be reflective of the high antigen load within the tumor microenvironment, which is similar to the progressive exhaustion exhibited by T cells in the setting of chronic virus infection. By contrast, the defect in degranulation appeared to be a general event within the tumor microenvironment, which affected all infiltrating CD8 þ T cells. Therefore, we interpret these results to suggest that vaccine-induced TILs are dysfunctional within the tumor microenvironment at all times owing to antigen-specific and antigen-independent events. As a result of these dysfunctions, high frequencies of CD8 þ T Representative data from one of the three independent experiments are shown in panel b. Asterisks denote significant differences: *Po0.05. Pooled data from three independent experiments using 10-15 mice per group are shown in panel c. Asterisks denote significant differences: **Po0.01.
High-dose chemotherapy enhances tumor vaccination N Grinshtein et al cells are required to overcome their limited activity and mediate tumor regression. However, as the CD8 þ T cell response has a defined kinetic consisting of an expansion and a contraction phase after immunization, tumor regression was only observed around the peak of the response (approximately 7-10 days after immunization) and tumors subsequently relapsed as T-cell response naturally fade during the contraction phase. Indeed, our observation that relapsed B16F10 tumors do not become resistant to DCT-specific immune effectors supports the argument that relapse is due to insufficient T-cell function rather than emergence of TEVs. The findings of this paper reinforce a number of parameters that should be considered for a future vaccine design. First, foreign antigens allow for a higher vaccineinduced immune response in the tumor-bearing hosts. Therefore, tumor-specific antigens, which arise from mutations are likely better candidates for vaccine antigens than non-mutated TAAs. Second, the functionality of the CD8 þ T cells within the tumor is more important than the functionality of the cells within the periphery. Third, vaccination strategies that can maximally expand CD8 þ T cells are required. As such, prime/boost strategies, such as those described recently for immunization against HIV and malaria should be developed. 41, 42 Although these strategies are difficult to evaluate in murine models owing to the short time frame of the tumor growth, they can be evaluated in human trials where tumor exhibits a longer term of growth.
Materials and methods
Mice
Six-to eight-week-old female C57BL/6 mice were obtained from Charles River Breeding Laboratories (Montreal, Quebec, CA). DCT-deficient mice 43 were bred at McMaster University. All of our investigations have been approved by the McMaster Animal Research Ethics Board.
rAd and immunizations
All rAd vectors used in this study contain deletions of E1 and E3 regions. 44 The expression cassettes were inserted into the E1 region under the control of the murine CMV promoter and the SV40 polyadenylation sequence. The rAd vectors were propagated using 293 cells and purified using CsCl gradient centrifugation as described previously. 45 AdhDCT encodes the full-length human DCT (also known as TRP-2), 15 AdLCMV GP expresses the sequence corresponding to residues 33-41 and 61-80 of the lymphocytic choriomeningitis virus glycoprotein. AdLacZ expresses b-galactosidase as a transgene and was used as a negative control. 46 For immunizations, 10 8 or 10 9 pfu of adenovirus vector was prepared in sterile phosphate-buffered saline and injected into both rear thighs (50 ml per thigh).
Peptides
The immunodominant MHC (major histocompatibility complex) class I peptides of hDCT (DCT 180À188 SVYDFFVWL) and LCMVGP (GP 33À41 ; KAVYN-FATM) as well as MHC II peptides of hDCT (hDCT 88À102; RKFFHRTCKCTGNFA) and LCMVGP (GP 61À80 , GLKGPDIYKGVYQFKSVEFD) were purchased from Biomer Technologies (Hayward, CA). Peptides were dissolved in dimethylsulfoxide and stored at À20 1C.
Tumor cell lines and tumor model B16F10 murine melanoma cell line was cultured in F11 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. B16F10 cells stably transfected with the GP 33À41 eptiope (B16GP33) were kindly provided by Dr H Pircher 26 and cultured in the presence of G418 (400 mg ml
À1
; Sigma-Aldrich, St Louis, MO) to maintain transgene expression. Tumors were induced by intradermal injection of 10 5 tumor cells in 30 ml of sterile phosphate-buffered saline. Tumor size was monitored daily and measured three times a week using calipers. In studies involving the analysis of TILs, tumors were dissected and cut into small pieces before incubation with collagenase type I (0.05 mg ml
) dissolved in Hank's buffered salt solution for 1 h at 37 1C. Cells were then passed through 70-mm cell strainers and centrifuged. The pelleted cells were resuspended in RPMI 1640 with 10% serum (cRPMI) and further enriched for TILs by using LympholyteM density gradient (Cedarlane, Burlington, ON, CA). In studies involving the analysis of TEVs, tumors were explanted minced into small pieces with scalpel and digested in 0.02% collagenase/0.2% dispase (Boehringer, Laval, Quebec, CA) for 1 h at 37 1C. Recovered tumor cells were then washed with phosphate-buffered saline, cultured for 72 h at 37 1C, 5% CO 2 and injected back into either naive or earlier immunized animals.
Cytotoxic treatments
Cyclophosphamide (Sigma, St Louis, MO) was dissolved in sterile saline and administered by intraperitoneal injection every other day (150 mg kg À1 ) for a total of three doses. In experiments involving sublethal irradiation, animals were irradiated with either 250 or 550 rads administered through 137 Cs-g-irradiation source (Gamma Cell 40; Nordion, Kanata, ON, Canada).
Flow cytometry reagents, acquisition and analysis
The following antibodies used for flow cytometry were purchased from BD Pharmingen (Oakville, ON, CA): anti-CD28 (clone 37.51), anti-CD49d (clone R1-2), anti-CD8a (clone 53-6.7), anti-CD4 (clone RM4-5), anti-IFN-y (clone XMG1.2), anti-TNFa (clone MP6-XT22), anti-IL2 (clone JES6-5H4), anti-CD107a (clone 1D4B). Anti-FoxP3 (clone FJK-16s) was purchased from e-Bioscience (San Diego, CA). Data from stained samples were acquired using either an LSRII or a FACSCanto (BD Pharmingen) and analyzed using FlowJo (Treestar, Ashland, OR).
Intracellular cytokine staining
Intracellular cytokines were visualized using a protocol as described earlier. 45 Briefly, aliquots of 2 Â 10 6 cells splenocytes were placed in 96-well U-bottomed plates and restimulated with or without specific peptide (1 mg ml À1 ) for 5 h at 37 1C, 5% CO 2 in the presence of anti-CD28 and anti-CD49d antibodies (2 mg ml À1 each). Brefeldin A (BD Pharmingen) was added for the last 3 h of the incubation at a concentration of 5 mg ml À1 .
Degranulation assay
We used the protocol described earlier by Betts et al. 47 with minor modifications. Aliquots of 2 Â 10 6 cells splenocytes were placed in 96-well U-bottomed plates and restimulated with or without specific peptide (1 mg ml À1 ) for 5 h at 37 1C, 5% CO 2 in the presence of anti-CD28 and anti-CD49d antibodies (2 mg ml À1 each) and CD107a-FITC antibodies (BD Pharmingen). Brefeldin A (BD Pharmingen) was added for the last 3 h of the incubation at the concentration of 5 mg ml
À1
. Cells were Abbreviations: DCT, dopachrome tautomerase; WT, wild type. a DCT-deficient mice were inoculated with 1 Â 10 5 B16F10 cells intradermal (i.d.), injected with CTX 5 days later and immunized with AdhDCT. Relapsing tumors were excised 3-4 weeks post-immunization (at the point of relapse) and transplanted into either untreated mice (group C) or AdhDCT-immunized mice (group B). AdhDCT-immunized mice that were injected with fresh B16F10 tumors served as controls (group A). The percentage of tumor-free mice was quantified 30 days post-tumor challenge. Pooled results from two independent experiments using 10 mice per group are shown.
subsequently stained with anti-CD8, followed by staining for intracellular IFN-g.
In vivo CTL Spleen and lymph node cells from naive C57BL/6 mice were separated into two groups. One group was pulsed with 1 mg ml À1 DCT 180À188 (SVYDFFVWL) for 1 h at 37 1C and then labeled with 5 mM 5,6-carboxyfluorescein succinimidyl ester (CFSE). The other group was incubated for 1 h at 37 1C in the absence of peptide and then labeled with 0.5 mM CFSE. Five million cells from each group were mixed and injected into AdhDCT-vaccinated High-dose chemotherapy enhances tumor vaccination N Grinshtein et al recipients. After 4 h of target cell transfer, spleen and lymph node cells were harvested and analyzed by FACS. The percentage of specific lysis was determined by the comparison of fluorescent intensities between specific and nonspecific populations using the formula described by Coles et al.
48
Avidity analysis Splenocytes were restimulated using serial 10-fold dilutions of DCT 180À188 (SVYDFFVWL) peptide, ranging from 1 mM to 1 pM, and stained for CD8 þ and IFN-g. 49 Functional avidity was determined as the peptide concentration that resulted in the stimulation of 50% of the maximum number of IFN-g þ CD8 þ T cells. 50 
Statistical analysis
Student's t-tests were conducted using Microsoft Excel, and differences were considered significant at Po0.05. Data are presented as mean ± s.e.m. Differences in the survival of mice were analyzed using the Kaplan-Meier method, and groups were compared using the log-rank test.
